{"id":"havrix-720","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site soreness or swelling"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"1-5","effect":"Fever"},{"rate":"5-10","effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) hepatitis A virus antigen that triggers both humoral and cellular immune responses. This leads to the production of protective antibodies (anti-HAV) and memory B cells, conferring long-term immunity against hepatitis A infection. The 720 designation refers to the antigen content (720 ELISA units per 0.5 mL dose).","oneSentence":"Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:42.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis A infection in adults and children"}]},"trialDetails":[{"nctId":"NCT06298708","phase":"PHASE3","title":"Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2024-04-27","conditions":"HAV, Hepatitis A, Hep A","enrollment":120},{"nctId":"NCT00139113","phase":"PHASE4","title":"Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"1996-09","conditions":"Hepatitis A","enrollment":248},{"nctId":"NCT03654664","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-06-20","conditions":"Hepatitis A Vaccine","enrollment":119},{"nctId":"NCT05613127","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs","status":"UNKNOWN","sponsor":"Boryung Biopharma Co., Ltd.","startDate":"2022-12","conditions":"Hepatitis A, Hep A","enrollment":106},{"nctId":"NCT01041573","phase":"PHASE3","title":"Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-03","conditions":"Encephalitis","enrollment":1869},{"nctId":"NCT00289731","phase":"PHASE4","title":"Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11-24","conditions":"Hepatitis B, Hepatitis A","enrollment":596},{"nctId":"NCT01307436","phase":"PHASE3","title":"Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2007-03-14","conditions":"Hepatitis A","enrollment":327},{"nctId":"NCT01352793","phase":"PHASE3","title":"A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-11","conditions":"Meningitis, Meningococcal","enrollment":5715},{"nctId":"NCT01405677","phase":"PHASE2","title":"Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2004-06","conditions":"Hepatitis A","enrollment":308},{"nctId":"NCT00483470","phase":"PHASE3","title":"Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-06","conditions":"Hepatitis A","enrollment":720},{"nctId":"NCT01349829","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2010-03","conditions":"Hepatitis A","enrollment":251},{"nctId":"NCT01252680","phase":"PHASE4","title":"Immunogenicity and Interchangeability of Two Inactivated Hepatitis A Vaccines","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2010-04","conditions":"Hepatitis A","enrollment":303},{"nctId":"NCT00125047","phase":"PHASE4","title":"Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2001-10","conditions":"Typhoid, Paratyphoid Fever","enrollment":27231},{"nctId":"NCT00125008","phase":"PHASE4","title":"Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2003-05","conditions":"Typhoid, Paratyphoid Fever","enrollment":37673}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Havrix 720","genericName":"Havrix 720","companyName":"Crucell Holland BV","companyId":"crucell-holland-bv","modality":"Biologic","firstApprovalDate":"","aiSummary":"Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}